Clinical trial
Wellbutrin XL for Dysthymic Disorder
NCT00225251 · St. Luke's-Roosevelt Hospital Center, Other · Completed
Key facts
| NCT number | NCT00225251 |
|---|---|
| Title | Wellbutrin XL for Dysthymic Disorder |
| Official title | Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL |
| Lead sponsor | St. Luke's-Roosevelt Hospital Center, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Dysthymic Disorder |
| Intervention type | Drug, Other |
| Interventions | bupropion XL, Placebo |
| Enrollment | 18 |
| Start date | Nov 1, 2004 |
| Primary completion | May 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Sep 23, 2005 |
| Last update posted | Nov 26, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: